All-trans retinoic acid ( DrugBank: Retinoic acid )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
94	Primary sclerosing cholangitis	2

94. Primary sclerosing cholangitis

---

Clinical trials : 142 /  Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03359174 (ClinicalTrials.gov)	May 29, 2018	27/11/2017	An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis	An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis	Cholangitis, Sclerosing	Drug: All-trans retinoic acid	Yale University	NULL	Terminated	18 Years	80 Years	All	2	Phase 2	United States
2	NCT01456468 (ClinicalTrials.gov)	October 2011	14/10/2011	Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis	Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis - A Human Pilot Study	Cholangitis, Sclerosing	Drug: Oral all-trans retinoic acid (ATRA)	Yale University	Mayo Clinic	Completed	18 Years	80 Years	Both	19	Phase 1	United States